Neuroblastoma Drugs Market Share

North American Market Forecast

North America industry is estimated to hold largest revenue share of 36% by 2037. This growth is attributed to the rise in technologically enhanced drugs along with the increase in incidences of neuroblastoma. As of 2020 estimations more than USD 190 billion was spent on healthcare of cancer in 2015 and was projected to increase to over USD 200 billion in 2020 in the U.S. Further, growing investments in the healthcare sector and approval of orphan drugs for the treatment of neuroblastoma are boosting the market growth. The rising number of people undergoing chemotherapy and drug treatments to reduce further complications of the disease is anticipated to propel the market growth. The market growth is also attributed to the growing patient population with immune suppression with age and other disease conditions. The increasing change in food habits and high consumption of plastic containers and silver foil containers for food delivery is also estimated to rise the market growth. The growing population with less physical activity and high exposure to radiation that initiate mutations in the gene are the reason for the market growth. More people suffering from immune suppressive disorders such as diabetes are more prone to diseases causing major threats to the incidence of cancer tumors and is estimated to drive market growth.

Europe Market Forecast

The European neuroblastoma drugs market is estimated to be the second largest, registering a share of about 27% by the end of 2037. The growth of the market can be attributed majorly to the increasing prevalence of cancer in children along with the increase in spending on cancer treatment. Additionally, the first drug approved for the cure of neuroblastoma that is anti-GD2 is witnessing huge demand owing to its site-specific action and no cytotoxic effects on the body. Further, the increasing newborn population in the region along with the development of advanced novel therapies for the treatment of neuroblastoma is fostering the market growth. Furthermore, increased awareness of the diagnosis and treatment of neuroblastoma has permitted the focus on new tumor targets for the advancement of cell-mediated immunotherapy medicines for cancer. Hence, these factors are estimated to fuel the growth of the market over the forecast period. The market in Europe is estimated to witness significant growth on the account of the rising number of child healthcare centers for the treatment of cancer along with the increasing awareness related to good health.

APAC Market Statistics

Further, the market in the Asia Pacific, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The growth of the market can be attributed majorly to the increasing aging population and poor healthcare facilities. The Asia Pacific region is anticipated to be the fastest growing market on the back of the presence of emerging nations leading to a surge in children’s cancer base. The occurrence of COVID-19 leading to a decrease in the immune system’s capacity to fight against any disease is estimated to drive market growth. The number of cases of neuroblastoma in children and the elderly with a lack of awareness of the disease is also anticipated to hike the growth of the market. The increasing research institutes of cancer that conduct clinical trials for the discovery of new drugs to prevent the spread of the disease is expected to rise the market growth. The increasing number of healthcare centers with chemotherapy, drug therapy, and reimbursement policies to enhance the living standards of people in the region is also estimated to fuel the market growth in the coming years.